Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (OLMA) Healthcare & Pipeline Overview

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for women's cancers, with a lead product candidate, OP-1250, an estrogen receptor antagonist and selective ER degrader, currently in Phase 1/2 clinical trials, positioning them in the competitive biotechnology sector.

What Is the Investment Thesis for OLMA?

Olema Pharmaceuticals presents a focused investment opportunity within the biotechnology sector, driven by its lead drug candidate, OP-1250. Currently in Phase 1/2 clinical trials, positive data readouts could serve as a significant catalyst for stock appreciation. The company's specialization in women's cancers, particularly ER+ breast cancer, addresses a substantial market with unmet needs. The market capitalization stands at $1.42 billion, reflecting investor confidence in the pipeline's potential. A beta of 2.18 indicates higher volatility compared to the market, which investors may want to evaluate. Key risks include clinical trial setbacks, regulatory hurdles, and competition from established pharmaceutical companies. Successful development and commercialization of OP-1250 are critical value drivers.

Based on FMP financials and quantitative analysis

OLMA Key Highlights

• Lead product candidate OP-1250 is in Phase 1/2 clinical trials targeting ER+ HER2- breast cancer.
• Market capitalization of $1.12B reflects investor sentiment regarding the company's pipeline.
• The company focuses on therapies for women's cancers, addressing a significant market need.
• Olema Pharmaceuticals has 96 employees, indicating a focused and agile operational structure.
• Beta of 2.18 suggests higher volatility compared to the overall market.

Who Are OLMA's Competitors?

OLMA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OLMA's Key Strengths?

• Lead product candidate OP-1250 targeting a significant unmet need in ER+ breast cancer.
• Experienced management team with expertise in drug development and commercialization.
• Strong intellectual property position protecting its drug candidates.
• Focus on a specific therapeutic area (women's cancers) allows for specialization and efficiency.

What Are OLMA's Weaknesses?

• Clinical-stage company with no currently approved products generating revenue.
• Reliance on the success of OP-1250, posing a risk if the drug fails in clinical trials.
• Limited financial resources compared to larger pharmaceutical companies.
• High cash burn rate associated with clinical development activities.

What Could Drive OLMA Stock Higher?

• Data readouts from the ongoing Phase 1/2 clinical trial of OP-1250.
• Potential initiation of new clinical trials for OP-1250 in additional indications.
• Advancement of preclinical programs into clinical development.
• Potential strategic partnerships or collaborations with other pharmaceutical companies.

What Are the Key Risks for OLMA?

• Negative return on equity (-45.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for OP-1250.
• Competition from other companies developing therapies for ER+ breast cancer.
• Regulatory hurdles and changes in the regulatory landscape.
• High cash burn rate associated with clinical development activities.
• Reliance on the success of OP-1250.

What Are the Growth Opportunities for OLMA?

• Expansion of OP-1250 Clinical Trials: Olema has the opportunity to expand the clinical trials for OP-1250 into additional indications and combination therapies. This includes exploring OP-1250's efficacy in earlier lines of treatment or in combination with other anti-cancer agents. Success in these expanded trials could significantly broaden the addressable market and increase the drug's commercial potential. The timeline for these expansions is dependent on the results of the ongoing Phase 1/2 trials, with potential for new trials initiating within the next 1-2 years.
• Advancement of Pipeline Programs: Olema can advance its preclinical programs into clinical development, diversifying its pipeline beyond OP-1250. This includes identifying and developing new drug candidates targeting other mechanisms relevant to women's cancers. A diversified pipeline would reduce the company's reliance on a single asset and provide multiple avenues for growth. The timeline for advancing preclinical programs into the clinic typically ranges from 2-3 years, depending on preclinical data and regulatory requirements.
• Strategic Partnerships and Collaborations: Olema could pursue strategic partnerships and collaborations with other pharmaceutical companies or research institutions. These partnerships could provide access to new technologies, funding, or development expertise. Collaborations could also accelerate the development and commercialization of Olema's pipeline programs. The timing and nature of these partnerships are difficult to predict, but they could significantly impact the company's growth trajectory.
• Geographic Expansion: Olema has the opportunity to expand its operations beyond the United States into international markets. This includes conducting clinical trials in other countries and eventually commercializing its products globally. Geographic expansion would increase the company's reach and revenue potential. The timeline for international expansion would likely follow successful clinical development and regulatory approval in the United States, with potential for expansion within 3-5 years.
• Acquisition or Licensing of New Assets: Olema can acquire or license new assets that complement its existing pipeline and expertise. This includes acquiring rights to new drug candidates, technologies, or intellectual property. Acquisitions and licensing deals can provide Olema with new growth opportunities and accelerate its development efforts. The availability and timing of these opportunities are unpredictable, but they could significantly enhance the company's long-term prospects.

What Opportunities Does OLMA Have?

• Positive clinical trial results for OP-1250 could lead to accelerated regulatory approval.
• Expansion of OP-1250 into additional indications or combination therapies.
• Strategic partnerships with larger pharmaceutical companies to co-develop or commercialize products.
• Acquisition of new assets or technologies to expand its pipeline.

What Threats Does OLMA Face?

• Clinical trial failures or delays could negatively impact the company's valuation.
• Competition from other companies developing therapies for ER+ breast cancer.
• Regulatory hurdles and changes in the regulatory landscape.
• Difficulty in raising additional capital to fund clinical development activities.

What Are OLMA's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in developing therapies for women's cancers.
• Clinical data supporting the efficacy and safety of OP-1250.
• Established relationships with key opinion leaders in the oncology field.

What Does OLMA Do?

Olema Pharmaceuticals, Inc., established in 2006 and headquartered in San Francisco, California, is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of innovative therapies specifically for women's cancers. Originally incorporated as CombiThera, Inc., the company rebranded to Olema Pharmaceuticals, Inc. in March 2009, signaling a refined focus on addressing unmet medical needs in women's oncology. The company's primary focus is on developing therapies that target estrogen receptor-positive (ER+) breast cancer, one of the most prevalent forms of the disease. Their lead product candidate, OP-1250, is an estrogen receptor (ER) antagonist and a selective ER degrader (SERD). OP-1250 is currently undergoing Phase 1/2 clinical trials for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema's approach involves creating targeted therapies designed to overcome resistance mechanisms and improve outcomes for patients with women's cancers. The company operates primarily within the United States, conducting research and development activities to advance its pipeline of novel cancer treatments.

What Products and Services Does OLMA Offer?

• Develop targeted therapies for women's cancers.
• Focus on estrogen receptor-positive (ER+) breast cancer.
• Develop estrogen receptor (ER) antagonists and selective ER degraders (SERDs).
• Conduct Phase 1/2 clinical trials for lead product candidate OP-1250.
• Discover and commercialize therapies for recurrent, locally advanced, or metastatic breast cancer.
• Target human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

How Does OLMA Make Money?

• Develop and patent novel therapeutic candidates for women's cancers.
• Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
• Seek regulatory approval from the FDA and other regulatory agencies.
• Potentially commercialize approved products directly or through partnerships.

What Industry Does OLMA Operate In?

Olema Pharmaceuticals operates within the competitive biotechnology industry, specifically targeting the oncology market. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for breast cancer therapies is substantial and growing, driven by increasing incidence rates and advancements in treatment options. Olema's focus on ER+ breast cancer positions it within a well-defined segment of the oncology market. Key trends include the development of targeted therapies, personalized medicine, and immunotherapies. Olema's approach with OP-1250 aligns with the trend toward targeted therapies designed to overcome resistance mechanisms.

Who Are OLMA's Key Customers?

• Patients with recurrent, locally advanced, or metastatic ER+ HER2- breast cancer.
• Oncologists and other healthcare professionals who treat women's cancers.
• Hospitals and cancer centers that provide cancer care.
• Potential pharmaceutical partners for collaboration and licensing agreements.

ROE -46%Key Financial Metrics

Return on equity for Olema Pharmaceuticals, Inc. stands at -45.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -14.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.1%, the inverse of the P/E and a quick read on earnings relative to price.

How Olema Pharmaceuticals, Inc. Is Valued

Olema Pharmaceuticals, Inc. carries a market capitalization of $1.12B, placing it in the small-cap category. Relative to its peer group, OLMA's quantitative score of 47/100 is below the peer average of 87/100.

F-Score 1/9Financial Health

Olema Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.36 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Olema Pharmaceuticals, Inc. revenue of about $2.3M for fiscal 2026, with EPS near $-2.21. The estimate reflects 6 contributing analysts.

OLMA Financials

OLMA Latest News

OLMA Analyst Consensus

OLMA MoonshotScore

Olema Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources